Oruka Therapeutics (NASDAQ:ORKA) Sees Large Volume Increase – Still a Buy?

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) saw unusually-high trading volume on Friday . 1,210,388 shares traded hands during trading, an increase of 3% from the previous session’s volume of 1,177,664 shares.The stock last traded at $87.8740 and had previously closed at $83.04.

Analyst Ratings Changes

ORKA has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 23rd. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a report on Thursday, April 30th. Barclays raised their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research note on Monday, April 27th. BTIG Research reiterated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Monday, July 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Stock Performance

The stock has a market cap of $5.59 billion, a P/E ratio of -47.78 and a beta of -0.35. The firm has a 50-day moving average price of $72.51 and a 200-day moving average price of $53.28.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, research analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Insider Buying and Selling at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 9,999 shares of the stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $84.63, for a total value of $846,215.37. Following the completion of the transaction, the senior vice president directly owned 15,312 shares in the company, valued at $1,295,854.56. This trade represents a 39.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13. Following the transaction, the director directly owned 38,743 shares of the company’s stock, valued at approximately $2,716,271.73. This trade represents a 24.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 188,406 shares of company stock worth $12,019,683. Corporate insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada boosted its position in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the 4th quarter worth approximately $37,000. PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics during the 3rd quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd bought a new position in Oruka Therapeutics during the 4th quarter valued at approximately $67,000. Finally, Russell Investments Group Ltd. purchased a new position in Oruka Therapeutics during the third quarter valued at $43,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.